A research team has identified the essential role of a structural protein in the silencing of the inactive X chromosome, a process that prevents both copies of the same gene from being expressed in female mammals, which carry two copies of the X chromosome.
Disruptive science can have a significant impact outside of our own domains of research and into our personal lives. Keeping abreast of these developments can help prepare and inspire.
FDA commissioner, Scott Gottlieb said that he expects the FDA to approve 40 gene therapies by 2022 in a fireside chat at the 2018 BIO International Convention.
Probably not. But there is an increasing demand for people with data and computing skills, and the life sciences sector in California may be losing the battle with Silicon Valley for those people.
Scientists now have easy access to the full power of CRISPR, without any learning curve, thanks to Synthego’s Engineered Cells Portfolio.
Researchers have synthesized the first artificial human prion, a dramatic development in efforts to combat a devastating form of brain disease that has so far eluded treatment and a cure.
New research may explain the link between a high level of iron in the body and prostate cancer.
A 21-gene test performed on tumours could enable most patients with the most common type of early breast cancer to safely forgo chemotherapy, according to a landmark study.
Researchers have devised a magnetic control system to make tiny DNA-based robots move on demand, and much faster than recently possible.
Starting about 7,000 years ago, and extending over the next two millennia, recent studies suggest, the genetic diversity of men—specifically, the diversity of their Y chromosomes—collapsed.
The Norwegian Academy of Science and Letters, which is one of the world’s richest science awards in the world, have announced its award will go to three discoverers of the genome-editing tool, CRISPR-Cas9.
U.S. regulators have put a halt on a clinical trial planned to use CRISPR technology on sickle-cell patients due to ‘unspecified questions’, CRISPR Therapeutics said on Wednesday.